MicroPort Scientific Corporation Cash Flow Conversion Efficiency
MicroPort Scientific Corporation cash flow conversion efficiency. Based on the latest financial reports, MicroPort Scientific Corporation (MSK) has a cash flow conversion efficiency ratio of -0.053x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-81.89 Million ≈ $-95.74 Million USD) by net assets (€1.54 Billion ≈ $1.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MicroPort Scientific Corporation (2013–2025)
Cash flow conversion efficiency of MicroPort Scientific Corporation from 2013 to 2025. This chart illustrates how MicroPort Scientific Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MSK live share price for real-time trading data and today's change.
MicroPort Scientific Corporation Cash Flow Conversion Ratio Explained
MicroPort Scientific Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MicroPort Scientific Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MicroPort Scientific Corporation ranked by their cash flow conversion efficiency. Also see market value of MicroPort Scientific Corporation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FAP Agri Tbk PT
JK:FAPA
|
0.099x |
|
Allient Inc.
NASDAQ:ALNT
|
0.045x |
|
Harbin Hatou Investment Co Ltd
SHG:600864
|
0.090x |
|
Shinsegae
KO:004170
|
0.029x |
|
TES Co. Ltd
KQ:095610
|
0.075x |
|
Telecom Argentina SA ADR
NYSE:TEO
|
0.106x |
|
Offcn Education Technology Co Ltd
SHE:002607
|
0.076x |
|
Adecoagro S.A
F:ACD
|
0.067x |
Annual Cash Flow Conversion Efficiency for MicroPort Scientific Corporation (2013–2025)
The table below shows the annual cash flow conversion efficiency of MicroPort Scientific Corporation from 2013 to 2025. Review MicroPort Scientific Corporation free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.50 Billion ≈ $1.75 Billion |
€69.13 Million ≈ $80.82 Million |
0.046x | +206.22% |
| 2024-12-31 | €1.14 Billion ≈ $1.34 Billion |
€-49.67 Million ≈ $-58.07 Million |
-0.043x | +73.75% |
| 2023-12-31 | €1.40 Billion ≈ $1.64 Billion |
€-231.87 Million ≈ $-271.08 Million |
-0.165x | +13.70% |
| 2022-12-31 | €1.79 Billion ≈ $2.10 Billion |
€-343.30 Million ≈ $-401.36 Million |
-0.192x | -64.90% |
| 2021-12-31 | €2.22 Billion ≈ $2.59 Billion |
€-257.53 Million ≈ $-301.08 Million |
-0.116x | -594.78% |
| 2020-12-31 | €1.39 Billion ≈ $1.62 Billion |
€-23.20 Million ≈ $-27.12 Million |
-0.017x | -141.33% |
| 2019-12-31 | €653.97 Million ≈ $764.55 Million |
€26.45 Million ≈ $30.92 Million |
0.040x | -74.57% |
| 2018-12-31 | €528.95 Million ≈ $618.39 Million |
€84.13 Million ≈ $98.36 Million |
0.159x | -28.08% |
| 2017-12-31 | €439.45 Million ≈ $513.77 Million |
€97.19 Million ≈ $113.62 Million |
0.221x | -7.16% |
| 2016-12-31 | €346.48 Million ≈ $405.07 Million |
€82.53 Million ≈ $96.49 Million |
0.238x | +146.45% |
| 2015-12-31 | €317.83 Million ≈ $371.57 Million |
€30.72 Million ≈ $35.91 Million |
0.097x | +86.59% |
| 2014-12-31 | €343.74 Million ≈ $401.87 Million |
€17.81 Million ≈ $20.82 Million |
0.052x | -64.98% |
| 2013-12-31 | €390.43 Million ≈ $456.46 Million |
€57.75 Million ≈ $67.52 Million |
0.148x | -- |
About MicroPort Scientific Corporation
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; an… Read more